Medtech company DeepCure announced on August 31 that it presented the domestic clinical results of its laparoscopic-based extravascular renal denervation (eRDN) system, HyperCure, at the European Society of Cardiology Annual Congress (ESC Congress 2026).


DeepCure Presents 'HyperCure' Results at ESC 2026: "A New Treatment Option for Resistant Hypertension" View original image

On August 30 (local time), during the "Treatments for Hypertension" session held in Munich, Germany, Hyuk Jin Park, Professor of Cardiology at Chonnam National University Medical School, released research results observing changes in 24-hour ambulatory blood pressure (ABP) patterns after HyperCure procedures in patients with resistant hypertension.


This is the world’s first-in-human (FIH) clinical study conducted on patients with resistant hypertension whose blood pressure was not controlled despite taking three or more antihypertensive drugs. The study was a collaborative effort by cardiology teams from major general hospitals in Korea, including Chonnam National University Hospital, Seoul National University Hospital, Seoul National University Bundang Hospital, Severance Hospital, Hanyang University Hospital, Asan Medical Center, and Seoul St. Mary’s Hospital.


The clinical results showed that patients who underwent the HyperCure procedure experienced a significant reduction in blood pressure over a 24-hour period three months after the procedure. The 24-hour average systolic blood pressure (ASBP) decreased from 154 mmHg before the procedure to 125.4 mmHg three months later, an average reduction of 28.6 mmHg. The 24-hour average diastolic blood pressure (ADBP) dropped from 98.7 mmHg to 79.2 mmHg, representing an average decrease of 19.5 mmHg.


The research team explained that the procedure was also effective in suppressing blood pressure spikes during the “morning blood pressure surge” period, which is associated with an increased risk of cardiovascular and cerebrovascular disease.


Professor Park stated, “This clinical trial demonstrated that the extravascular RDN procedure effectively suppresses blood pressure increases during both daytime and morning periods. These data indicate that HyperCure could become a viable treatment alternative for patients with resistant hypertension who require continuous 24-hour blood pressure management.”



A representative from DeepCure said, “Following the submission of our Investigational Device Exemption (IDE) for the U.S. FDA premarket approval (PMA) track, ESC 2026 has further validated HyperCure’s efficacy in lowering 24-hour ambulatory blood pressure. Based on these clinical data, we plan to pursue strategic partnerships with global medtech companies and discuss commercialization.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing